This cross-sectional study examines the use of telemedicine for buprenorphine inductions among individuals with commercial insurance or Medicare Advantage during the temporary repeal of the Ryan Haight Act requirement of in-person evaluation before prescribing buprenorphine during to the COVID-19 pandemic.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739765 | PMC |
| http://dx.doi.org/10.1001/jamanetworkopen.2021.42531 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Content analysis of perceptions of combined pharmacobehavioral treatment for American Indian people with opioid use disorder.
Psychol Addict Behav
January 2025
Department of Psychiatry and Behavioral Sciences, University of Washington.
Objective: Both opioid misuse and overdose mortality have disproportionately impacted the American Indian population. Although medications for opioid use disorder, such as buprenorphine (BUP-NX), are highly effective in reducing overdose mortality, questions have been raised about the cultural acceptability of Western medical approaches in this population. Understanding patients' desired recovery pathways can lead to more culturally appropriate, patient-centered, and effective approaches to opioid use disorder (OUD) treatment.
View Article and Find Full Text PDFComparative Effectiveness of Buprenorphine Adherence with Telemedicine versus In-person for Rural and Urban Patients.
J Am Pharm Assoc (2003)
December 2024
Vanderbilt University Medical Center, Department of Biomedical Informatics.
Background: Policy changes during the COVID-19 pandemic allowed buprenorphine to be prescribed for opioid use disorder (OUD) via telemedicine without an in-person visit. A recently proposed change will limit buprenorphine access to 30 days without an in-person visit. Given that people living in rural areas may be disproportionally impacted by this change, we sought to better understand how buprenorphine adherence may be impacted by requiring in-person visits.
View Article and Find Full Text PDFBreaking barriers: Assessing the feasibility and acceptability of telemedicine-assisted buprenorphine induction for opioid use disorder in India.
Indian J Psychiatry
October 2024
Department of Psychiatry, Drug Deaddiction and Treatment Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Article Synopsis
- The study explored the acceptability and feasibility of telemedicine-assisted buprenorphine induction (TABI) for treating opioid use disorder in India.
- Among the 60 patients enrolled, a high retention rate of 88.3% during the TABI program and 83.3% at the 3-month follow-up was observed.
- Patient satisfaction was moderate, with 58.3% satisfied, but only 25% would recommend TABI, indicating the need for additional research to enhance its effectiveness and wider implementation.
Patient and provider experiences with opioid use disorder care delivered via telehealth: A systematic mixed-studies review.
Drug Alcohol Depend
January 2025
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Introduction: Since the onset of the COVID-19 pandemic and loosening of some opioid use disorder (OUD) treatment regulations in the U.S. and Canada, there has been a rapid rise in the use of telehealth for buprenorphine induction, maintenance, and counseling (tele-bupe).
View Article and Find Full Text PDFRedefining low-threshold buprenorphine access in an integrated mobile clinic program: Factors associated with treatment retention.
J Subst Use Addict Treat
November 2024
Johns Hopkins University School of Medicine, Division of Infectious Diseases, Baltimore, MD, USA; Baltimore City Health Department, Baltimore, MD, USA. Electronic address:
Introduction: The Spot mobile clinic provides low-threshold buprenorphine integrated with clinical and social services in Baltimore City, MD. In 2021, The Spot modified practices to improve engagement including providing extended prescriptions, reducing frequency of toxicology testing, giving up to six months to stabilize on medication, offering maximum doses (up to 32 mg total) daily, and utilizing telemedicine. This study characterizes care retention by examining both the total time in care and the percentage of time with buprenorphine prescription coverage during these practice changes, and examines factors associated with retention.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!